Based: Louisville, CO
Investors: Adams Street Partners, Allianz Private Equity Partners, Eminent Venture Capital, GC&H Partners
HealthCare Ventures, Lilly Ventures, Medica Venture Partners, Morgenthaler Ventures, Pac-Link Management Corporation, Sequel Venture Partners, Undisclosed Corporate Investor, Undisclosed Investor, Undisclosed Venture Firm, WRF Capital, Yasuda Enterprise Development
Scoop: GlobeImmune's researchers have been using recombinant yeast--Saccharomyces cerevisiae--that is genetically modified to express a protein that triggers a killer T cell response directed at diseased cells. These therapies are called Tarmogens. A Phase II trial for GI-4000, its pancreatic cancer drug, is currently underway. It's also preparing a separate trial for hepatitis C drug GI-5005-02. GlobeImmune was featured as one of FierceBiotech's Emerging Drug Developers.
GlobeImmune lands $41M venture round. Report